Lyophilized Factor IX Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia B, such as plasma-derived and recombinant Factor IX, have limitations including short half-life, frequent dosing, and high incremental recovery requirements, which do not provide prolonged protection from bleeding.
Innovation Solution
A pre-lyophilization formulation comprising Factor IX polypeptide, buffering agents, stabilizing agents, bulking agents, and surfactants, which allows for improved stability, reduced reconstitution time, and increased shelf-life of the lyophilized product.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If plasma-derived or recombinant Factor IX is used for treating hemophilia B, then Factor IX replacement therapy is achieved, but the half-life is short requiring frequent dosing
Solution Approach 1:
The patent changes the physical and chemical parameters of Factor IX by lyophilizing it with specific excipients (buffering agents, stabilizing agents, bulking agents, and surfactants) to create a stable solid-state formulation. This parameter change from liquid to solid state enables prolonged protection and reduced dosing frequency while maintaining therapeutic efficacy
Solution Approach 2:
The patent creates a composite material system by combining Factor IX with multiple excipients including buffering agents (e.g., histidine), stabilizing agents (e.g., sucrose, mannitol), bulking agents, and surfactants (e.g., polysorbate). This composite formulation provides both therapeutic function and extended stability, achieving prolonged protection from bleeding episodes
2Quantity of substance
If Factor IX is purified from plasma, then active Factor IX concentrate is obtained, but the purification process is very difficult due to low concentration
Solution Approach 1:
The patent performs preliminary concentration of Factor IX in the liquid formulation before lyophilization, achieving a concentrated formulation that freezes and lyophilizes efficiently. This preliminary action reduces the volume to be processed and simplifies the overall manufacturing process while maintaining high Factor IX concentration in the final product
3Reliability
If recombinant Factor IX is used, then Factor IX replacement is achieved, but incremental recovery is lower requiring higher doses
Solution Approach 1:
The patent optimizes the formulation parameters including pH, ionic strength, and excipient concentrations to enhance the stability and bioavailability of recombinant Factor IX. These parameter changes improve the incremental recovery of rFIX, allowing achievement of therapeutic efficacy with optimized dosing
4Ease of operation
If lyophilization is performed with standard fill volume, then processing is simplified, but reconstitution time is increased and stability is reduced
Solution Approach 1:
The patent optimizes the fill volume parameter to less than 5 mL (preferably less than 4 mL or less than 3 mL) which changes the thermal and mass transfer characteristics during lyophilization. This parameter change enables faster lyophilization cycles and shorter reconstitution times while maintaining or improving product stability through the optimized formulation composition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves improved stability and extended shelf-life of Factor IX, reducing the frequency of dosing and enhancing the duration of protection against bleeding episodes in hemophilia B patients.
Implementation Method 1
The present invention is directed to a pre-lyophilization formulation comprising: (a) a Factor IX (FIX) polypeptide having FIX coagulation activity; (b) a buffering agent; (c) a stabilizing agent; (d) a bulking agent; and (e) a surfactant
Data Source
AI summary
The present invention provides, among other things, pre-lyophilization formulations, reconstituted formulations, and lyophilate powder compositions comprising a Factor IX (FIX) polypeptide. The present invention also provides lyophilization methods for producing lyophilate powder comprising a FIX polypeptide.